Phenotypic profile and molecular mechanism of resistance in carbapenemase-producing Enterobacterales and

Pedro Kurtz, Pedro F Del Peloso, Bruno Rocha Pribul, Arthur M Albuquerque, Bianca B P Antunes, Grazielle Vianna Ramos, Fernando A Bozza

Abstract read

PubMed Full text at PMC Publisher

In one paragraph

Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Nacubactam: a review on mechanistic insights and therapeutic promise for combating β-lactam resistance among multidrug-resistant Gram-negative pathogens.Annals of medicine and surgery (2012) · 2026
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Pedro KurtzDor Institute of Research and Education, Rio de Janeiro, Brazil.

Pedro F Del PelosoRichet Laboratory, Rio de Janeiro, Brazil.

Bruno Rocha PribulInstituto Oswaldo Cruz (IOC), FIOCRUZ, Rio de Janeiro, Brazil.

Arthur M AlbuquerqueSchool of Medicine, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.

Bianca B P AntunesDepartment of Industrial Engineering (DEI), Pontifical Catholic University of Rio de Janeiro (PUC-Rio), Rio de Janeiro, Brazil.

Grazielle Vianna RamosDor Institute of Research and Education, Rio de Janeiro, Brazil.

Fernando A BozzaDor Institute of Research and Education, Rio de Janeiro, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/Objectives: Carbapenemase-producing Enterobacterales and Methods: A prospective multicenter study was conducted across 12 hospitals in Rio de Janeiro. A total of 150 Enterobacterale Results: IMR resistance was identified in 34.5% of Conclusion: This study highlights the emergence of significant resistance to imipenem-relebactam in Brazil, driven by both enzymatic and non-enzymatic mechanisms. Ongoing molecular surveillance and tailored treatment strategies are essential to address the evolving threat of multidrug-resistant Gram-negative infections in endemic regions.

Indexed as

antimicrobial therapycarbapenemasegram-negativeimipenem-relebactammulti-drug resistant

Identifiers

PMID41321817

DOI10.3389/fmicb.2025.1689777

PMCPMC12661512

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.